Vanguard Group
RUBY

Vanguard Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Vanguard Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,676,669
Closed -$293K – 4610
2022
Q4 		$293K Sell
1,676,669
-28,619
-2% -$7.82K ﹤0.01% 4228
2022
Q3 		$740K Sell
1,705,288
-231,905
-12% -$174K ﹤0.01% 4092
2022
Q2 		$1.65M Sell
1,937,193
-393,532
-17% -$661K ﹤0.01% 3891
2022
Q1 		$12.8M Sell
2,330,725
-915,916
-28% -$5.82M ﹤0.01% 3020
2021
Q4 		$31.4M Buy
3,246,641
+11,634
+0.4% +$161K ﹤0.01% 2614
2021
Q3 		$57.8M Sell
3,235,007
-7,396
-0.2% -$161K ﹤0.01% 2287
2021
Q2 		$79.1M Buy
3,242,403
+143,801
+5% +$3.6M ﹤0.01% 2118
2021
Q1 		$82.1M Buy
3,098,602
+689,847
+29% +$10.1M ﹤0.01% 2061
2020
Q4 		$18.3M Buy
2,408,755
+39,481
+2% +$234K ﹤0.01% 2681
2020
Q3 		$11.9M Sell
2,369,274
-789,856
-25% -$4.18M ﹤0.01% 2705
2020
Q2 		$18.9M Buy
3,159,130
+154,697
+5% +$913K ﹤0.01% 2456
2020
Q1 		$13.4M Buy
3,004,433
+15,776
+0.5% +$117K ﹤0.01% 2481
2019
Q4 		$28.4M Buy
2,988,657
+84,826
+3% +$821K ﹤0.01% 2366
2019
Q3 		$22.8M Buy
2,903,831
+178,114
+7% +$2.08M ﹤0.01% 2423
2019
Q2 		$42.9M Buy
2,725,717
+614,759
+29% +$9.92M ﹤0.01% 2185
2019
Q1 		$38.2M Buy
2,110,958
+1,116,709
+112% +$17.1M ﹤0.01% 2225
2018
Q4 		$16M Buy
994,249
+22,217
+2% +$405K ﹤0.01% 2540
2018
Q3 		$23.3M Buy
+972,032
New +$22.2M ﹤0.01% 2512

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Vanguard Group's RUBY Position: Q1 2023 in Review

Vanguard Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 1,676,669 shares — an estimated $293K sold.

Vanguard Group first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $82.1M in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Vanguard Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 1,676,669 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $293K.
  • Vanguard Group first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Vanguard Group's Rubius Therapeutics, Inc position peaked at $82.1M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.